Pfizer (PFE) Common Equity (2009 - 2026)

Pfizer (PFE) has 18 years of Common Equity data on file, last reported at $90.4 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $90.4 billion, changed 0.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.4 billion (changed 0.26% YoY), and the FY2025 annual result was $86.8 billion, down 1.95% from the prior year.
• Common Equity improved to $90.4 billion in Q1 2026 per PFE's latest filing, from $86.8 billion in the prior quarter.
• Over five years, Common Equity peaked at $101.2 billion in Q2 2023 and troughed at $82.7 billion in Q2 2022.
• A 5-year average of $91.6 billion and a median of $90.6 billion in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity soared 160.16% in 2022, then declined 11.4% in 2024.
• A 5-year view of Common Equity shows it stood at $95.9 billion in 2022, then slipped by 6.91% to $89.3 billion in 2023, then declined by 0.89% to $88.5 billion in 2024, then slipped by 1.95% to $86.8 billion in 2025, then climbed by 4.18% to $90.4 billion in 2026.
• Business Quant data shows PFE's Common Equity at $90.4 billion in Q1 2026, $86.8 billion in Q4 2025, and $93.1 billion in Q3 2025.